Join
Live feed
·
PRReleasevia Quantisnow
Sangamo Therapeutics Inc. logo

Sangamo Therapeutics Advances Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry Disease

ByQuantisnow·Wall Street's wire, on your screen.

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track SGMO (Sangamo Therapeutics Inc.) and more on Quantisnow.